Results - Announcements
Senores Pharmaceuticals Ltd share price inched up 1.05% to Rs 1324.05 after the company's net profit jumped 20.20% to Rs 36.6 crore, while revenue from operations slightly gained 6.73% to Rs 192.33 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.58 lakh crore, rising 4.26%. It has marginally improved by 3.87% over last one week and ticked higher by 0.06% in last one month while the market capitalization of Senores Pharmaceuticals Ltd has edged up by 10.11% and 1.73% in the same period respectively.
Profit before tax (PBT) of Senores Pharmaceuticals Ltd stood at Rs 47.58 crore in Q3 FY26, surging by 17.08% year-on-year, and rallying 20.58% quarter-on-quarter. EBITDA came in at Rs 49 crore, expanding by 71.19% YoY and declining 4.38% sequentially.
Total expenses posted a minor rise of 6.25% to Rs 144.92 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 28.39 crore, easing 8.86% YoY, while employee benefits expense was at Rs 32.41 crore, improving by 8.36% YoY.
For the TTM ended FY26, revenue from operations witnessed a strong growth of 85.65% to Rs 398.25 crore, while net profit soared by 78.36% to Rs 58.34 crore, compared to previous TTM. EBITDA surged by 4460% to Rs 70.44 crore, and PBT surged 182.85% to Rs 70.57 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 45.92 crore in FY26, as against Rs 25.7 crore in FY25.
Senores Pharmaceuticals Ltd rallied 69.02% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 13.45% during the same period.